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of systemic small vessel vasculitis in children. HSP most
commonly affects children between 2 and 6 years of age.
The presence of purpuric rash (100%) is essential to the
diagnosis. Other clinical characteristics of HSP include
abdominal pain or gastrointestinal bleeding (50e75%),
arthralgia and/or arthritis (up to 82%), and hematuria and/
or proteinuria (20e60%).1 The disease generally has acute
onset, and a benign and self-limiting course that lasts an
average of 4 weeks.1 Immunoglobulin A nephropathy
(IgAN), however, has an insidious onset and slow progres-
sive nature. IgAN is the most common form of glomerulo-
nephritis in both children and adults. It mostly affects
young adults. Renal biopsy findings of IgAN and HSPN are
indistinguishable due to the presence of IgA-containing
immune complex deposits in the renal mesangium.2 It has
been speculated that HSP is a systemic form of IgAN.
The clinical features of children with IgAN are variable,
going from asymptomatic microscopic hematuria with/
without proteinuria to gross hematuria. A small number of
patients present with clinical signs of the nephrotic or
nephritic syndrome. About 10e30% of pediatric patients
have slow progressive disease, leading to end-stage renal
disease in adulthood.3 Poor prognostic factors include
older age, heavy proteinuria, renal insufficiency, hyper-
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classification of IgAN identified four pathological elements
that were of prognostic value in predicting the outcome of
renal function: mesangial hypercellularity, endocapillary
proliferation, segmental glomerulosclerosis/adhesion, and
tubular atrophy/interstitial fibrosis.4 These findings offer
the possibility to identify patients who are most likely to
progress to renal failure at the time of biopsy.
In IgAN patients with microscopic hematuria and/or low-
grade proteinuria, it is not known whether therapy is
necessary. If proteinuria is >1 g/1.73 m2 body surface
area per day, the initiation of treatment with angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin
receptor blockers is generally accepted. More aggressive
treatment with corticosteroids and immunosuppressants
should be reserved for children with a poor response to
ACEIs/angiotensin receptor blockers or who have hyper-
tension, nephrotic syndrome, reduced renal function or
advanced histologic lesions.2 Clinical trials have shown
conflicting results for the efficacy of omega-3 poly-
unsaturated fatty acids in IgAN.5
HSPN is often manifested by microscopic hematuria
with/without low-grade proteinuria, mostly within 6 weeks
of the initial presentation of HSP. Nephritis or nephrotic
syndrome develops in about 20% of children with HSPN
(6e7% of children with HSP) at disease onset.1 HSPN is the
most serious long-term complication of HSP. Corticoste-
roids, immunosuppressants such as azathioprine, cyclo-
phosphamide, cyclosporine and mycophenolate mofetil
have been used in the treatment of patients with severe
HSPN.6 Poor prognostic factors are nephritic/nephrotic
syndrome, and advanced renal histology such as crescents& Formosan Medical Association. All rights reserved.
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general, it is estimated that 1e3% of all HSPN patients will
ultimately develop chronic kidney disease. Patients pre-
sented with nephritic or nephrotic syndrome have a poor
prognosis, with a 20e40% risk of chronic kidney disease or
end-stage renal disease.6
Although the etiology is unknown, IgAN and HSP are both
IgA-containing immune-complex-mediated diseases and are
triggered by common viral or bacterial infection. In HSP, IgA
anti-endothelial cell antibodies play a role in vascular
damage.7 Increased production of underglycosylated IgA1
in the circulation and renal mesangium is characteristic
for IgAN and HSPN. Such “nephritogenic” IgA1 is deficient
in galactose or prematurely sialylated in the hinge region
O-linked glycans. This results in aberrant exposure of
N-acetylgalactosamine-containing neoepitopes that are
then recognized by naturally occurring IgG or IgA1 anti-
bodies, leading to the formation of immune complexes.
Circulating large molecular mass IgA1- and IgG-containing
immune-complexes are less efficiently cleared from the
circulation by the asialoglycoprotein receptor in the liver
and tend to bind to glomerular mesangial cells through
CD71 (the transferrin receptor). Mesangial cells undergo
proliferation and overproduction of cytokines and growth
factors leading to glomerulosclerosis. Complement activa-
tion through alternative and lectin pathways, and other
immune cells’ recruitment and activation also participate
in glomerular and tubulointerstitial injury.8 Impaired
homing of IgA-producing plasma cells from mucosa to the
bone marrow that leads to the overproduction of under-
glycosylated IgA1 in circulation rather than in the mucosa
might also contribute to disease pathogenesis in the animal
model of IgAN (ddY mice).9
Our understanding of the genetic susceptibility, patho-
genesis and treatment of HSP are less clear than for IgAN.
Underglycosylation of IgA1 is assumed to have a pivotal role
in the pathogenesis of both IgAN and HSPN. Levels of
underglycosylated IgA1 and IgG against underglycosylated
IgA1 are elevated in the serum of patients with IgAN and
HSPN, compared with HSP patients without nephritis or
controls.10 The detection of such antibodies in the serum
might offer sensitive and specific, noninvasive diagnostic
tests, and they might even be used as disease activity
markers in the future. There have been debates about
glycosylation defects due to genetic polymorphisms in the
glycosylation enzyme or as a consequence of aberrant
mucosal immune response. Longitudinal studies to deter-
mine whether the glycosylation defects of IgA1 persist
following the resolution of clinical symptoms of HSPN
should be able to answer this question.HSP and IgAN might represent different ends of
a continuous spectrum of disease. The key factors in
deciding the direction of systemic or local involvement
have not, however, been identified. Moreover, the research
into HSP is greatly limited due to the lack of a suitable
animal model. Genome-wide association studies have
provided valuable information through the discovery of
novel pathogenic pathways in IgAN, and this could be also
applied to patients with HSP and HSPN. We hope there will
be further studies on the glycosylation of IgA1 molecules
and receptors in the immune deposits in the skin, joints or
gastrointestinal tract in HSP patients.
The current therapy has not been proven to alter the
natural history of either disease. Thus far there is little
evidence to indicate the most effective treatment for HSPN
and IgAN, especially in children. Large controlled clinical
trials with prolonged follow-up are needed to address these
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